Target intelligence / Profile preview

V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1) (TCIRG1)

Target
TCIRG1
Molecular classification
V-type ATPase, Proton pump, Ion transporter
01

Overview

V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1), also known as T-cell immune regulator 1, is a multi-pass membrane protein that functions as the a3 subunit of the V0 domain within the vacuolar-type H+-ATPase (V-ATPase) complex [UniProt Q13488]. It is highly expressed in osteoclasts, where it is indispensable for the acidification of the resorption lacuna, allowing for the dissolution of bone mineral during remodeling [Nature Genetics 25.3 (2000): 343-346]. TCIRG1 also plays a significant role in the immune system, specifically in T-cell activation and the regulation of intracellular pH in various organelles [Gene 220.1-2 (1998): 41-49]. Mutations in the TCIRG1 gene are responsible for approximately 50% of cases of infantile malignant osteopetrosis, a severe genetic disorder characterized by abnormally dense bone and bone marrow failure [UniProt Q13488, Nature Genetics 25.3 (2000): 343-346]. In the context of oncology, TCIRG1 is frequently overexpressed in various cancers, where it facilitates extracellular acidification, promoting protease activity and tumor cell invasion [Journal of Biological Chemistry 284.23 (2009): 15490-15500]. Although it represents a potential therapeutic target for metabolic bone diseases and metastatic cancer, the high conservation of V-ATPase subunits across tissues presents significant challenges for achieving isoform-specific inhibition and avoiding systemic toxicity [PNAS 85.21 (1988): 7972-7976, British Journal of Pharmacology 151.3 (2007): 323-333].

Other names
T-cell immune regulator 1TIRC7OC116a3Vph1OPTB1Atp6iV-type proton ATPase 116 kDa subunit a isoform 3
02

Mechanism of action

Inhibition of the V0 domain of the V-type ATPase complex, thereby blocking proton translocation across the plasma membrane or organelle membranes.

03

Biological functions

Bone resorptionAcidification of intracellular compartmentsT-cell activationInsulin secretionpH regulation
04

Disease associations

Infantile malignant osteopetrosisOsteopetrosis autosomal recessive 1Cancer metastasisAutoimmune disease
05

Safety considerations

Systemic toxicity due to ubiquitous V-ATPase expressionPotential for lysosomal storage-like dysfunctionImpaired immune responseAltered insulin signaling
06

Interacting drugs

Bafilomycin A1

4 more in the full profile.

07

Biomarkers

TCIRG1 gene mutationsC-terminal telopeptide of type I collagen (CTx)Tartrate-resistant acid phosphatase (TRAP)

Beyond the preview

Go deeper on V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1) (TCIRG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1) (TCIRG1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call